Insulin Dosing Controller for Personalized Glycemic Management

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Manual calculation of insulin doses in hospitals leads to human error, workflow inefficiencies, and inconsistent protocols, increasing the risk of hypoglycemic events and sub-optimal glycemic management, particularly in patients with fluctuating blood sugars due to diabetes, trauma, or stress.

Innovation Solution

A clinical decision support system that analyzes patient data to calculate personalized insulin doses, considering blood glucose levels, patient information, and nutritional intake, and transitions between intravenous and subcutaneous insulin regimens, using a glucometer and dosing controller to administer insulin accurately and efficiently.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If manual calculation of insulin doses is used, then flexibility in treatment adjustment is maintained, but human error increases and reliability decreases

Engineering Contradiction:
Improveaccuracy of insulin dosingVSAvoidautomation of insulin dose calculation
Core Design Contradiction:
ReliabilityVSExtent of automation

Solution Approach 1:

The patent introduces a clinical decision support system as an intermediary between the healthcare provider and the patient. This system includes a processor that receives blood glucose measurements and patient information, then automatically calculates personalized insulin doses using algorithms. The system acts as a mediator that eliminates manual calculation errors while maintaining clinical oversight, directly resolving the contradiction between reliability and automation.

Inventive Principle:
Principle #24Intermediary (Mediator)

2Productivity

If complex paper protocols are used for insulin dosing, then comprehensive treatment guidelines are provided, but workflow efficiency decreases and paperwork increases

Engineering Contradiction:
Improveworkflow efficiencyVSAvoidcomplexity of dosing protocol
Core Design Contradiction:
ProductivityVSDevice complexity

Solution Approach 1:

The patent replaces the mechanical paper-based protocol system with an electronic computational system. The processor automatically executes complex dosing algorithms and generates insulin dose recommendations without requiring physical paperwork. This substitution eliminates the need for nurses to manually navigate complex paper protocols, directly improving workflow efficiency while maintaining comprehensive treatment guidelines through digital algorithms.

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

3Reliability

If multiple institutional protocols are used, then various treatment approaches are covered, but consistency of treatment decreases

Engineering Contradiction:
Improveconsistency of insulin dosingVSAvoidflexibility of treatment protocol
Core Design Contradiction:
ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent creates a universal clinical decision support system that can handle multiple treatment scenarios through a single platform. The processor is programmed with algorithms that accommodate different patient conditions, blood glucose levels, and insulin types, providing consistent dosing recommendations across various institutional protocols. This multi-functional system maintains treatment consistency while adapting to diverse clinical situations, resolving the contradiction between reliability and adaptability.

Inventive Principle:
Principle #6Universality (Multi-functionality)

Data Source

PatentEP3046601B1Insulin management
Publication Date: 2026.01.07 GLYTEC LLC
  • EP3046601B1 patent drawingFigure 1A
  • EP3046601B1 patent drawingFigure 1B
  • EP3046601B1 patent drawingFigure 1C

AI summary

A method (1600) of administering insulin mcludes receiving blood glucose measurements (BG) of a patient (10) at a data processing device (112) from a glucometer (124). The blood glucose measurements are separated by a time interval (ΤNext). The method also includes receiving patient information (208a) at the data processing device and selecting a subcutaneous insulin treatment (900, 1100, 1200, 1300, 1400) from a collection of subcutaneous insulin treatments. The selection is based on the blood glucose measurements and the patient information. The selection includes one or more of a subcutaneous standard program (900), a subcutaneous program without meal boluses (1100), a meal-by-meal subcutaneous program without carbohydrate counting ( 1200), a meal-by-meal subcutaneous program with carbohydrate counting (1300), and a subcutaneous program (1400) for non-diabetic patients. The method also includes executing, using the data processing device, the selected subcutaneous insulin treatment.